Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated transplant recipients

Nephrology Dialysis Transplantation

Volumn 16, Issue 1, 2001, Pages 141-146

  Renders, Lutz ^a   Mayer Kadner, Irmgard ^a   Koch, Christine ^a   Schärffe, Sabine ^a   Burkhardt, Klaus ^a   Veelken, Roland ^a   Schmieder, Roland E ^a   Hauser, Ingeborg A ^a,b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Atorvastatin; Cerivastatin; Cyclosporin A; Cytochrome P450; Hyperlipidaemia; Renal transplantation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CERIVASTATIN; CHOLESTEROL; CLONIDINE; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; METHYLPREDNISOLONE; MEVINOLIN; MIBEFRADIL; SIMVASTATIN; TRIACYLGLYCEROL; XENOBIOTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; FEMALE; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIPID BLOOD LEVEL; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RHABDOMYOLYSIS; RISK FACTOR;

EID: 0035165026     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.1.141     Document Type: Article

References (30)

1. Hyperlipidemia in renal transplant recipients: Natural history and response to treatment
2. Effects of cyclosporine therapy on plasma lipoprotein levels
3. The use of HMG-CoA reductase inhibitors to prevent accelerated graft artherosclerosis in heart transplant patients
4. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine
5. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine
6. Metabolism and drug interaction of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
7. Rhabdomyolyse bei mit Simvastatin und Cyclosporin behandelten Patienten: Rolle der Aktivität des Cytochrom-P450-Enzymsystems der Leber
8. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
9. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias
10. Cerivastatin
11. Pharmacokinetics of single-dose cerivastatin in subjects with normal and impaired renal function
12. Effect of itraconazole on the pharmacokinetics of atorvastatin
13. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
14. P-glycoprotein-mediated apical secretion of atorvastatin in caco-2 cell monolayers
15. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells
16. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
17. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
18. Examination of the potential interaction between HMG-CoA reductase inhibitors and cyclosporine in transplant patients
19. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
20. Human P-glycoprotein transports cyclosporine A and FK506
21. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs
22. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
23. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
24. Risk factors predicting chronic rejection of renal allografts
25. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics
26. Rhabdomyolysis induced by simvastatin and ketoconazole treatment
27. Case report: Rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin
28. Influence of oral felodipine on serum cyclosporine concentrations
29. Role of circulating lipid abnormalities in chronic renal allograft rejection
30. The effects of lipids on graft outcome